Search

Your search keyword '"Efremidis, Anna"' showing total 175 results

Search Constraints

Start Over You searched for: Author "Efremidis, Anna" Remove constraint Author: "Efremidis, Anna"
175 results on '"Efremidis, Anna"'

Search Results

1. Figure 1 from ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk

2. Figure 3 from ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk

3. Figure 6 from ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk

4. Table S2 from ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk

5. Data from ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk

6. Figure 4 from ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk

7. Supplementary Methods 1 from ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk

8. Figure 2 from ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk

9. Figure 5 from ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk

10. ENIGMA CHEK2gether Project:A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk

15. Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group

16. Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group

17. Case report 352

18. Insulin resistance: an independent risk factor for lung cancer?

19. Elevated Serum Leptin Levels: A Risk Factor for Non-Small-Cell Lung Cancer?

20. Validation and comparison of several published prognostic systems for patients with small cell lung cancer

21. Prognostic system in advanced NSCLC: A validation study by the ELCWP

22. Validation and comparison of published prognostic classification for survival in patients (pts) with small cell lung cancer (SCLC).

23. Prognostic factors for survival in patients with small cell lung cancer: validation study of a published classification

24. Daily low dose of cisplatin (P) radiochemotherapy for limited small cell lung cancer (SCCL): an European Lung Cancer Working Party phase III trial

25. A phase III randomized study comparing concomitant standard cisplatin (P) etoposide (E) and chest irradiation to concomitant etoposide plus daily cisplatin and chest irradiation as induction therapy for limited (LD) small-cell lung cancer (SCLC)

26. A phase III randomized study comparing concomitant standard cisplatin-etoposide and chest irradiation to concomitant etoposide plus daily cisplatin and chest irradiation as induction therapy for limited small cell lung cancer

27. A phase III randomised study comparing standard cisplatin (P)- etoposide (E) and chest irradiation to concomitant etoposide plus daily cisplatin and chest irradiation as induction therapy for limited (LD) small cell lung cancer (SCLC)

28. A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer

30. Chimiothérapie conventionnelle versus traitement séquentiel du cancer bronchique non à petites cellules 5CBNPC) avancé: une étude randomisée de phase III

31. A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer

32. Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: A study by the European Lung Cancer Working Party

33. Traitement des cancers bronchiques non à petites cellules: Maladies avancées (métastatiques). Les recommandations de pratique clinique de l'European Lung Cancer Working Party

34. Chemotherapy improves low performance status lung cancer patients

35. A randomised phase III trial by the ELCWP comparing sequential administration of cisplatin-based chemotherapy followed by a taxan and a cisplatin-based chemotherapy with the use of taxan as salvage treatment

36. A phase III randomised trial comparing sequential to standard chemotherapy in advanced non-small cell lung cancer (NSCLC)

37. Sequential versus standard chemotherapy in advanced non-small cell lung cancer: a phase III randomised trial

38. Second-line paclitaxel for primary or secondary failure in non-small cell lung cancer (NSCLC) initially treated with cisplatin-gemcitabine-ifosfamide (GIP) A preliminary analysis of a study by the ELCWP

39. European Lung Cancer Working Party Clinical Practice Guidelines. Non-small cell lung cancer: I. Early stages.

40. European Lung Cancer Working Party Clinical Practice Guidelines. Non-small cell lung cancer: III. Metastatic disease.

41. Traitement des cancers bronchiques non à petites cellules, non métastatiques et non résécables. Recommandations de pratique clinique de l'European Lung Cancer Working Party

42. Traitement des cancers bronchiques non à petites cellules et résécables. Recommandations de pratique clinique de l'European Lung Cancer Working Party

43. European Lung Cancer Working Party Clinical Practice Guidelines. Non-small cell lung cancer: II. Unresectable non-metastatic stages.

44. A feasibility study preparing to a phase III randomised trial comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. A trial conducted by the European Lung Cancer Working Party (ELCWP)

45. Clinicopathologic characteristics of triple-negative breast cancer and relationship to basal markers.

46. Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy

47. A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer

48. A new TNM classification is better than ISS at predicting survival in stage III unresectable non-small cell lung cancer (NSCLC)

49. A phase III randomized study comparing two different dose-intensity regimens as neoadjuvant chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small cell lung cancer

50. Resectability after two different dose-intensity chemotherapy regimens: analysis of a randomised trial in initialy unresectable stage III non small cell lung cancer

Catalog

Books, media, physical & digital resources